Shares of Atossa Genetics Inc (NASDAQ:ATOS) have been given a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that cover the company, Zacks Investment Research reports. One analyst has rated the stock with a strong buy rating.
Analysts have set a 12-month consensus target price of $10.00 for the company and are anticipating that the company will post ($0.48) EPS for the current quarter, according to Zacks. Zacks has also assigned Atossa Genetics an industry rank of 82 out of 255 based on the ratings given to related companies.
A number of research analysts have recently commented on the stock. Maxim Group reissued a “$2.47” rating and issued a $10.00 price objective on shares of Atossa Genetics in a research report on Wednesday, July 18th. ValuEngine raised shares of Atossa Genetics from a “hold” rating to a “buy” rating in a research report on Wednesday, July 4th.
Shares of ATOS opened at $1.47 on Wednesday. Atossa Genetics has a one year low of $1.41 and a one year high of $19.08.
Atossa Genetics (NASDAQ:ATOS) last announced its quarterly earnings data on Monday, August 13th. The company reported ($2.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($2.53). As a group, equities analysts forecast that Atossa Genetics will post -4.18 EPS for the current fiscal year.
Atossa Genetics Company Profile
Atossa Genetics Inc a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company is conducting a Phase 2 clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen, as well as treatment for breast density and other breast health conditions.
Featured Article: Asset Allocation, Balancing Your Investments
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Atossa Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Genetics and related companies with MarketBeat.com's FREE daily email newsletter.